key: cord-0857594-jbk57wbs authors: Le Bihan Benjamin, Christine; Simonnet, Julien-Aymeric; Rocchi, Mathieu; Khati, Inès; Ménard, Estelle; Houas-Bernat, Emilie; Méric, Jean-Baptiste; Bousquet, Philippe-Jean title: Monitoring the impact of COVID-19 in France on cancer care: a differentiated impact date: 2022-03-10 journal: Sci Rep DOI: 10.1038/s41598-022-07984-w sha: 45402716acd0352c7dc2ff057e7f4fc335c5aa24 doc_id: 857594 cord_uid: jbk57wbs The COVID-19 pandemic has had a substantial and lasting impact on care provision, particularly in the field of cancer care. National steering has helped monitor the health situation and adapt the provision and organisation of care. Based on data from the French administrative healthcare database (SNDS) on the entire French population (67 million people), screening, diagnostic and therapeutic activity was monitored and compared 2019 on a monthly basis. A noteworthy decline in all activities (with the exception of chemotherapy) was observed during the first lockdown in France. Over the months that followed, this activity returned to normal but did not make up for the shortfall from the first lockdown. Finally, during the lockdown in late 2020, cancer care activity was conserved. In brief, in 2020, the number of mammograms decreased by 10% (− 492,500 procedures), digestive endoscopies by 19% (− 648,500), and cancer-related excision by 6% (− 23,000 surgical procedures). Hospital radiotherapy activity was down 3.8% (− 4400 patients) and that in private practice was down 1.4% (− 1600 patients). Chemotherapy activity increased by 2.2% (7200 patients), however. To summarize, COVID-19 had a very substantial impact during the first lockdown. Safeguarding cancer care activity helped limit this impact over the months that followed, but the situation remains uncertain. Further studies on the medium- and long-term impact on individuals (survival, recurrence, after-effects) will be conducted. | (2022) 12:4207 | https://doi.org/10.1038/s41598-022-07984-w www.nature.com/scientificreports/ suggest a reduction in survival associated with increased waiting times to undergo screening [10] [11] [12] , diagnosis, or treatment [13] [14] [15] . This had led the health authorities to propose new strategies, prioritise cancer patients, and take action in the uncertainty. In this context, the French National Cancer Institute has set up, with support from the French Ministry for Health, a national steering and monitoring committee in concert with major national and regional stakeholders in cancer care and user representatives. It is organised in a regional structure via local and regional steering committees, helping pass on alerts and important information, and report, on a national level, innovative and exemplary organisations along with issues encountered on a regional level. The Institute has also developed activity monitoring and steering scorecards aimed at national, regional and local stakeholders. They are intended to monitor prevention, screening, and care activity in hospital and nonhospital settings. The purpose of this study is to present the cancer care activity monitoring and steering scorecards, estimate the impact of the health crisis due to COVID-19, and present the measures adopted to limit their effects. Data source. Several data sources were used. For non-hospital activity, data from the French administrative healthcare database (SNDS), medico-administrative data covering the entire French population 16 were used. These data are updated on a monthly basis. For hospital activity, the study relied on activity data recorded by all French hospital facilities (Medicalised information system programme) for all inpatients and outpatients. Since the pandemic, these data have been updated on a weekly basis. Although they are also found in the SNDS, these data are processed on the secure ATIH (French agency for information on hospital management) due to quicker availability. Three months after the activity completion date, these two data sources are sufficiently exhaustive for processing purposes. Data. Activity monitoring concerns the analysis of medical procedures linked with cancer care for diagnosis, screening, or treatment (excision, chemotherapy, radiotherapy). Lines were selected according to the public health policy in France. For diagnosis, the lines of analysis are upper and lower digestive tract endoscopies, bronchial and ENT endoscopies (fibroscopies), prostate biopsies as per the CCAM (Common classification of medical procedures) list. For screening, the lines are mammograms under the organised breast cancer screening programme or outside this screening programme, faecal blood screening tests for the organised colorectal cancer screening programme, cytological analyses or human papillomavirus detection for organised cervical screening or outside the organised cervical screening programme as per the different lists concerned (CCAM, NABM -list of medical pathology procedures, and NGAP -general list of professional procedures). For cancer care-related excisions, the lines of analysis concern the 6 categories of cancer sites for which activity is subject to authorisation 17 and to minimum activity thresholds in France: digestive tract (stomach, liver, pancreas, colorectal), gynaecological (ovarian), breast, chest, urological, and ENT (ear, nose, throat) and maxillofacial cancers (CCAM). Oesophageal cancers are excluded from digestive tract, chest and ENT cancers, and presented separately for a better understanding. Stays with cancer removal surgery are identified by coding cancer as the main diagnosis and a surgical removal procedure. Thus, only histologically confirmed cancers should be counted. For chemotherapy, the data used were from hospital admissions specifying a primary diagnostic code Z511 (ICD 10 -International Classification of Diseases); and, for radiotherapy, hospital admissions specifying a primary diagnostic code Z5101 (ICD 10), and private practice CCAM radiation procedures. Analyses. Monthly comparisons (number and percent) of care consumption for the years 2019 and 2020 were made to account for seasonal factors in care activity. Ethic. All methods were carried out in accordance with relevant guidelines and regulations. Data were pseudonymized prior to performing analyses Access to SNDS and PMSI data is subject to authorisation from CNIL (French data protection authority)-decree of 26 December 2016 No. 2016-1871. The study covered the entire French population, i.e. 67 million people, sex-ratio 0,93 and mean age 42,1 years. (Table 1, Fig. 1 ). Diagnostic and screening activity was substantially impacted by the first lockdown. For digestive tract endoscopies, the shortfall was − 43. Similar findings were observed for bronchial and ENT fibroscopies and prostate biopsies. An overall increased in colorectal screening and decrease in cervical screening (HPV test and cytopathology) were observed between 2019 and 2020. (see Table 1 and Fig. 1 ). Regardless of the type of activity (diagnosis, screening and excision), the impact of the first lockdown is roughly the same: a shortfall in March, which worsened in April, partial recovery in May. The activity in the months following the easing of lockdown restrictions failed to bridge the gap observed, with activity reaching a similar level to the previous year. Over the last months of the year, greater activity was observed in 2020 for mammograms, prostate biopsies, and excisions as a whole. Nevertheless, for oesophageal cancers and ENT cancers, the activity remained lower in 2020 compared to 2019 even at year end. Unlike the first lockdown, the restrictions applied from the end of October 2020 were not associated with a significant decrease in activity, suggesting a safeguarding of cancer care activity and the application of the guidelines issued following the first lockdown. As such, over 2020, a substantial shortfall in activity remains, in terms of diagnosis, screening, and excisions. For the organised colorectal cancer screening programme, the results are deceptive, as the slight difference needs to be put into perspective with the disruptions in the supply of tests in 2019. The main strength of this study is that it allowed regular monitoring of the health situation in cancer care based on exhaustive data, relating to prevention, screening, diagnosis, and care. The SNDS contains data from non-hospital settings and hospital data for the entire population. Although this medico-administrative database contains no clinical data, it enables effective monitoring of care activity. A further advantage of this study is that it covered a population of 67 million inhabitants, and included all patients regardless of their social or economic status or insurance scheme. Due to its exhaustive nature, it made it possible to monitor the health impact of the different lockdown periods, and of the different measures following the first lockdown and applied during subsequent months. A number of lessons can be taken from these scorecards. During the first lockdown in March 2020, a substantial decline in activity as a whole was observed, both for the diagnostic and treatment activity. In the case of the latter, a lag occurred with a slight decrease in activity during March, but a later recovery came in June after the lockdown was lifted in May. This particularly reflects the impact of the health crisis on scheduled activity www.nature.com/scientificreports/ (particularly surgical activity). Furthermore, the shortfall in activity was not bridged in the months that followed the lifting of the lockdown. A further lesson relates to the lockdown initiated in November 2020. Unlike the first lockdown, the directives given to safeguard diagnostic and therapeutic activities in cancer care appear to have been followed, thus limiting the impact of this further lockdown period. The impact of the health crisis is observed in many countries. For example, in the USA, several studies on medico-administrative databases report decreases of over 75% in breast, colorectal and cervical cancer screening activity during lockdown 12, 18, 19 . Similar findings are observed in Europe, with treatment-related activity also being impacted, with changes in practices and times to complete treatments [20] [21] [22] [23] [24] [25] . One limitation stems from the three-month time-frame for obtaining data, but scorecard processing is nonetheless not affected. Indeed, even though the aim is to enable accurate steering of the health crisis, these scorecards provide a good overview of the situation. This limitation is explained by the need to obtain exhaustive data. In the context of COVID-19, it is necessary to have daily monitoring of all hospitalisations due to COVID-19 in order to adapt health measures on a day-by-day basis. As regards cancer care activity monitoring, it is necessary to differentiate between a decrease in activity due to underreporting (lack of exhaustive data) and an actual decrease in activity. Furthermore, the measures adopted by the authorities on a national and local level and by www.nature.com/scientificreports/ healthcare professionals are measures to be applied over subsequent weeks or even months and do not require day-to-day steering. Following on from these scorecards, further processing may be conducted to study the impact on a department or regional level. This could be compared to the spread of the virus in these areas. Besides these scorecards which do not allow monitoring of diagnostic and treatment activity for each individual, it would be beneficial to conduct follow-up studies on cancer patients' care pathways. It will then be possible to estimate times to treatment, the potential transfer of activity particularly from surgery to chemotherapy and hormone therapy, or the forgoing of care. The number of chemotherapy inpatients is slightly higher in 2020, and there may be a carryover to oral therapies in non-hospital settings. The number of patients treated with radiotherapy is also lower, suggesting that the decrease in the number of sessions is not only due to the higher frequency of hypofractionated regimens. Follow-up studies will also help assess the impact of the current health crisis on recurrence and survival rates. The primary causes identified during the first wave are the closure of so-called "non-emergency" medical activities, and low uptake of care, whether from primary care professionals or from cancer care professionals. According to a study by the Observatory on non-uptake of social rights and public services (Odenore) and the French national health insurance fund 26 , 60% of those surveyed report having decided not to receive one care that they needed at least once during the first lockdown. Similarly, 50% are of the view that not receiving care worsened their health problems. It is difficult to obtain an accurate idea of the proportion attributable to these different causes of a shortfall in activity during the first wave and over time. Nevertheless, besides the waiting lists generated by the reduction in activity, non-uptake of care is likely to continue despite increased screening, diagnostic, and treatment capacities. Monitoring cancer care activity using SNDS data makes it possible to assess the impact of COVID-19 and the resulting health measures, particularly in the field of cancer care. The impact was greater in the first lockdown; however, despite the health measures adopted, the gap in activity does not appear to have been bridged. In some time, further studies will make it possible to assess the impact of COVID-19 not only on care pathways, recurrence, after-effects, and survival, but also on the forgoing of care. According to the European general data privacy regulation, an interested party interested in acceding data has to obtain an authorization from the French national ethic committee (CESREES) and the Cnil (French data protection authority) (contact: French national cancer institute). Préconisations pour l'adaptation de l' offre de soins des établissements accueillantes patients atteints de cancer dans le contexte de l' épidémie de COVID-19 Version 16 avril 2020 20l% E2% 80% 99ada ptati on% 20de% 20l% E2% 80% 99off re% 20de% 20soi ns% 20des% 20eta bliss ements% 20acc ueill ant% 20les% 20pat ients% 20att eints% 20de% 20can cer% 20dans% 20le% 20con texte% 20de% 20l% E2% 80% 99epi demie% 20de% Organisation de la consultation d'annonce et place de l'accompagnant dans le parcours du patient atteint de cancer Fiche% 20pra tique% 20can cer% 20et% 20COV ID-19% 20-% 20Org anisa tion% 20de% 20la% 20con sulta tion% 20d% E2% 80% 99ann once% 20et% 20pla ce% 20de% 20l% E2% 80% 99acc ompag nant% 20dans% 20le% 20par cours% 20du% 20pat ient% Organisation de la reprise d'activité de chirurgie des cancers Fiche% 20pra tique% 20can cer% 20et% 20COV ID-19% 20-% 20Org anisa tion% 20de% 20la% 20rep rise% 20d% E2% 80% 99act ivite% CC% 81% 20de% 20chi rurgie% 20des% 20can cers Organisation du rattrapage et de la continuité de l'activité de diagnostic et de traitement des cancers nécessitant un plateau technique et des ressources en anesthésie réanimation FICHE% 20PRA TIQUE% 20Org anisa tion% 20du% 20rat trapa ge% 20et% 20de% 20la% 20con tinui te% CC% 81% 20de% 20l% E2% 80% 99act ivite% CC% 81% 20de% 20dia gnost ic% 20et% 20de% 20tra iteme nt% 20des% 20can cers% 20ne% CC% 81ces sitant% 20un% 20pla teau% 20tec hnique% 20et% 20des% 20res sourc es% 20en% 20ane sthe% CC% 81sie-re% CC% 81ani mation Préconisations de priorisation des patients atteints de cancer pour la vaccination contre le SARS-CoV-2 20l% E2% 80% 99ada ptati on% 20de% 20l% E2% 80% 99off re% 20de% 20soi ns% 20des% 20eta bliss ements% 20acc ueill ant% 20les% 20pat ients% 20att eints% 20de% 20can cer% 20dans% 20le% 20con texte% 20de% 20l% E2% 80% 99epi demie% 20de% Continuité des activités des Centres régionaux de coordination des dépistages des cancers (CRCDC). Version du 3 avril Ministère des solidarités et de la santé The impact of the COVID-19 pandemic on cancer care Special Considerations in Adults and Children With Cancer [Internet]. National institute of health COVID-19 and cancer Effects of cancer screening restart strategies after COVID-19 disruption Decline and Rebound in Routine Cancer Screening Rates During the COVID-19 Pandemic Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic Impact of delay to surgery on survival in stage I-III colon cancer Cancer management during the COVID-19 pandemic: choosing between the devil and the deep blue sea Value of a national administrative database to guide public decisions: from the système national d'information interrégimes de l' Assurance Maladie (SNIIRAM) to the système national des données de santé (SNDS) in France Décret n°2007-388 du 21 mars 2007 relatif aux conditions d'implantation applicables à l'activité de soins de traitement du cancer Impact of COVID-19 on cancer care: how the pandemic is delaying cancer diagnosis and treatment for American Seniors Impact of the coronavirus disease 2019 (COVID-19) pandemic on imaging case volumes The impact of the COVID-19 pandemic on radiotherapy services in England, UK: a population-based study The COVID-19 pandemic and impact on breast cancer diagnoses: what happened in England in the first half of 2020 Impact of the COVID-19 pandemic on the detection and management of colorectal cancer in England: a population-based study Impact of the COVID-19 pandemic on diagnosis, stage, and initial treatment of breast cancer in the Netherlands: a population-based study Decreased incidence of oncology admissions in 75 helios hospitals in Germany during the COVID-19 pandemic Impact of COVID-19 on cancer service delivery: results from an international survey of oncology clinicians Caisse nationale de l'assurance maladie. Étude Odenore : près de 2 personnes sur 3 ont renoncé à se soigner pendant le premier confinement The authors would like to thank the French national health insurance fund (CNAM) and the French agency for information on hospital management for providing the data. The study was self-funded by the French national cancer institute. The authors declare no competing interests. Correspondence and requests for materials should be addressed to P.-J.B.Reprints and permissions information is available at www.nature.com/reprints.Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.